Our Pricing

Compare Saxenda, Wegovy & Mounjaro Weight Loss Treatments

Published on: June 03, 2026

This comprehensive saxenda wegovy mounjaro comparison uk guide helps you understand the key differences between the three leading prescription weight loss injections available through UK pharmacies. At Cured Pharmacy, our UK-registered clinical team provides transparent pricing and expert guidance to help you choose the most suitable treatment, with all three options requiring a clinical assessment by a UK prescriber before dispensing.

How Each Weight Loss Injection Works

Mounjaro (tirzepatide) represents the newest generation of weight loss medication, functioning as the UK's first dual GIP/GLP-1 receptor agonist licensed by the MHRA [1]. By activating both glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 pathways simultaneously, tirzepatide produces enhanced metabolic effects compared to single-pathway alternatives.

Wegovy (semaglutide) works exclusively through GLP-1 receptor activation, mimicking a natural hormone that regulates appetite and blood sugar levels [2]. Clinical trials demonstrate that once-weekly semaglutide injections slow gastric emptying, increase satiety signals to the brain, and reduce caloric intake without conscious restriction.

Saxenda (liraglutide) also targets GLP-1 receptors but requires daily administration rather than weekly dosing [3]. As the earliest GLP-1 treatment licensed for weight management in the UK, liraglutide established the safety profile that subsequent medications have built upon, though newer agents demonstrate superior weight reduction outcomes in head-to-head comparisons.

Clinical Trial Results: Weight Loss Outcomes Compared

The SURPASS-3 trial demonstrated that participants receiving the highest maintenance dose of Mounjaro achieved an average 22.5% total body weight reduction over 72 weeks [1]. This represented significantly greater weight loss than historical semaglutide data, with 63% of tirzepatide participants achieving at least 20% weight reduction.

Wegovy's pivotal STEP 1 trial showed participants lost an average 14.9% of their initial body weight over 68 weeks, with 86% achieving at least 5% weight loss [2]. These results established semaglutide as a substantial advancement over earlier weight management medications, with sustained effects throughout the trial duration.

Saxenda clinical trials reported average weight loss of 8% over 56 weeks in the SCALE Obesity and Prediabetes study [3]. Whilst demonstrating meaningful clinical benefit, liraglutide's daily dosing requirement and lower overall efficacy have positioned it as an alternative for patients who may not tolerate or respond optimally to newer weekly injections.

Real-World Effectiveness Considerations

Clinical trial results represent ideal conditions with high adherence and regular monitoring. Your UK prescriber will explain that individual responses vary based on baseline metabolic health, lifestyle modifications, medication tolerance, and adherence to the prescribed regimen. All three treatments require commitment to dietary changes and increased physical activity for optimal outcomes, as medications support rather than replace fundamental lifestyle interventions.

Dosing Schedules and Administration

Mounjaro utilises a gradual dose escalation protocol starting at 2.5mg weekly, increasing every four weeks through 5mg, 7.5mg, 10mg, 12.5mg, to a maximum maintenance dose of 15mg weekly [1]. The KwikPen injection device delivers pre-measured doses subcutaneously into the abdomen, thigh, or upper arm, with most patients self-administering after initial training.

Wegovy follows a similar escalation pattern beginning at 0.25mg weekly, progressing through 0.5mg, 1mg, 1.7mg, to the target maintenance dose of 2.4mg weekly [2]. The pre-filled pen design matches Mounjaro's user-friendly approach, requiring only once-weekly administration on the same day each week regardless of meal timing.

Saxenda requires daily subcutaneous injections starting at 0.6mg, increasing by 0.6mg increments weekly until reaching the maintenance dose of 3mg daily [3]. Whilst the daily schedule demands greater adherence commitment, some patients prefer the flexibility of adjusting timing around their daily routine rather than coordinating a specific weekly injection day.

Injection Technique and Storage Requirements

All three medications require refrigeration between 2-8°C before first use, though unopened pens may be kept at room temperature for limited periods as specified in patient information leaflets. Rotation of injection sites reduces the risk of lipodystrophy, and your dispensing pharmacy will provide detailed administration guidance. Cured Pharmacy's clinical team remains available for technique questions throughout your treatment course.

Side Effect Profiles: What to Expect

Gastrointestinal effects represent the most common side effects across all three treatments, typically manifesting as nausea, diarrhoea, constipation, and occasional vomiting [1][2][3]. These symptoms generally emerge during dose escalation phases and diminish as the body adapts to treatment, with severity often correlating to how quickly doses are increased.

Mounjaro's dual-receptor mechanism may produce slightly higher rates of gastrointestinal symptoms compared to semaglutide, particularly during initial titration [1]. Clinical trial data showed approximately 30-35% of participants experienced nausea, though severe cases leading to treatment discontinuation remained uncommon when appropriate dose escalation protocols were followed.

Wegovy and Saxenda demonstrate comparable gastrointestinal tolerability profiles, with nausea affecting approximately 20-44% of participants depending on final dose [2][3]. Serious adverse events remain rare across all three medications, but prescribers routinely monitor for pancreatitis risk, gallbladder complications, and changes in heart rate during treatment.

Managing Common Side Effects

Eating smaller, more frequent meals, avoiding high-fat foods, and staying well-hydrated significantly reduces gastrointestinal discomfort for most patients. Your UK prescriber may recommend temporarily pausing dose escalation if side effects become problematic, allowing your body additional adaptation time before progressing to higher maintenance doses. Never adjust your prescribed dose without consulting your healthcare provider.

Cost Comparison and UK Availability

Pricing structures for weight loss injections vary significantly across UK pharmacies, with Cured Pharmacy offering transparent upfront costs before consultation. Mounjaro treatment is available from £124.99 through our service, representing competitive UK pricing for this advanced dual-receptor medication with no hidden consultation fees or subscription requirements.

Treatment duration typically extends 12-24 months for optimal results, making long-term affordability an important consideration when selecting between options. Cured Pharmacy guarantees the lowest prices in the UK market whilst maintaining full regulatory compliance, with all medications sourced exclusively through licensed UK wholesalers and dispensed by our GPhC-registered pharmacy team.

Supply availability fluctuates across the UK market due to high demand and manufacturing capacity constraints. Our pharmacy team monitors stock levels continuously and communicates proactively with patients regarding any supply considerations, ensuring treatment continuity wherever possible through our established pharmaceutical supply relationships.

Choosing the Right Treatment for Your Circumstances

Your UK prescriber will assess multiple factors when recommending the most appropriate weight loss injection, including your baseline BMI, previous weight loss attempts, medical history, current medications, and personal preferences regarding dosing frequency. Patients with BMI ≥30 kg/m² or ≥27 kg/m² with weight-related comorbidities typically qualify for prescription weight loss medications under NICE guidance.

Mounjaro may be particularly suitable for patients seeking maximum weight reduction potential and who have not achieved adequate results with previous GLP-1 treatments. The dual-receptor mechanism offers advantages for individuals with more significant weight management challenges, though the higher cost and potentially increased gastrointestinal effects require consideration.

Wegovy represents an excellent balance of efficacy, tolerability, and convenience for many patients, with extensive real-world safety data and once-weekly administration. Saxenda remains a valuable option for those preferring daily dosing flexibility or who may have contraindications to higher-potency alternatives, subject to prescriber assessment of individual circumstances.

Starting Your Weight Loss Journey

Cured Pharmacy's free online consultation takes under three minutes and connects you with UK-registered prescribers who specialise in weight management. Our superintendent pharmacist Tarun Kumar (GPhC 2233073) oversees all clinical services, ensuring every patient receives appropriate assessment, ongoing monitoring, and expert pharmaceutical care throughout their treatment journey. All consultations remain completely confidential with 100% discreet packaging for home delivery.

Scientific References

1. Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine, 387(3), 205–216. https://doi.org/10.1056/NEJMoa2206038 [accessed 13 August 2026]
2. Wilding, J. P. H., Batterham, R. L., Calanna, S., et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 384(11), 989–1002. https://doi.org/10.1056/NEJMoa2032183 [accessed 13 August 2026]
3. Pi-Sunyer, X., Astrup, A., Fujioka, K., et al. (2015). A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management. New England Journal of Medicine, 373(1), 11–22. https://doi.org/10.1056/NEJMoa1411892 [accessed 13 August 2026]
4. National Institute for Health and Care Excellence. (2023). Obesity: identification, assessment and management (CG189). NICE. https://www.nice.org.uk/guidance/cg189 [accessed 13 August 2026]
5. NHS. (2026). Tirzepatide: a medicine to manage type 2 diabetes and treat obesity. https://www.nhs.uk/medicines/tirzepatide/ Accessed 13 August 2026.
6. NHS. (2026). Overweight and obesity in adults. https://www.nhs.uk/conditions/overweight-and-obesity/ Accessed 13 August 2026.
7. NHS England. (2026). Weight management injections. https://www.england.nhs.uk/ourwork/prevention/obesity/medicines-for-obesity/weight-management-injections/ Accessed 13 August 2026.

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication. Individual results may vary, and weight loss outcomes depend on adherence to prescribed treatment and lifestyle modifications.